$101.50
+0.45 (+0.45%)
Last updated: Apr 16, 2026 00:40
Fundamentals Overview
Abbott Laboratories is near the low of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
+30.5% upside vs price
Profitability
Risk (Beta)
0.78 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +30.5% upside vs price · Analyst grade: B+ · Sentiment improving (1 upgrade)
Pressures (Sell):
3M vs S&P 500: -19.2% · 3M vs Healthcare sector: -12.4%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 10, Neutral: 1, Outperform: 12, Overweight: 7.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $132.48; current price is $101.50. That’s a +30.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 27.18 |
| DCF value (model) | $132.48 (30.5% upside) |
| PEG (TTM) | N/A |
| P/B (TTM) | 3.4 |
| P/S (TTM) | 3.98 |
| P/FCF (TTM) | 23.85 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.58 |
| Quick Ratio (TTM) | 1.18 |
| Cash Ratio (TTM) | 0.52 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 14.72% |
| Gross margin (TTM) | 55.51% |
| Operating margin (TTM) | 18.16% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ABT.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Goldman Sachs | maintain | Buy | Buy | 2026-04-09 |
| Barclays | maintain | Overweight | Overweight | 2026-04-08 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-06 |
| BTIG | maintain | Buy | Buy | 2026-03-31 |
| Citigroup | maintain | Buy | Buy | 2026-03-11 |
| Barclays | maintain | Overweight | Overweight | 2026-02-02 |
| Freedom Broker | upgrade | Hold | Buy | 2026-01-29 |
| Citigroup | maintain | Buy | Buy | 2026-01-23 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-01-23 |
| BTIG | maintain | Buy | Buy | 2026-01-23 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-01-23 |
| Bernstein | maintain | Outperform | Outperform | 2026-01-23 |
| RBC Capital | maintain | Outperform | Outperform | 2026-01-23 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-01-23 |
| Bernstein | maintain | Outperform | Outperform | 2026-01-09 |
| Barclays | maintain | Overweight | Overweight | 2026-01-05 |
| BTIG | maintain | Buy | Buy | 2025-11-20 |
| Barclays | maintain | Overweight | Overweight | 2025-10-17 |
| Raymond James | maintain | Outperform | Outperform | 2025-10-16 |
| RBC Capital | maintain | Outperform | Outperform | 2025-10-16 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-10-16 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2025-10-16 |
| BTIG | maintain | Buy | Buy | 2025-10-15 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2025-10-07 |
| Bernstein | maintain | Outperform | Outperform | 2025-09-10 |
| BTIG | maintain | Buy | Buy | 2025-07-18 |
| Raymond James | maintain | Outperform | Outperform | 2025-07-18 |
| Citigroup | maintain | Buy | Buy | 2025-07-18 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-07-18 |
| Mizuho | maintain | Neutral | Neutral | 2025-07-18 |